Search

Displaying results 2791 - 2800 of 10000 in total
  1. Drug

    Gatralimab

    go.drugbank.com/drugs/DB16528
    Investigational

    Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial

  2. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed ...

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

  4. Drug

    Demeclocycline

    go.drugbank.com/drugs/DB00618
    Approved

    A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.

  5. Drug

    Amiloxate

    go.drugbank.com/drugs/DB11207
    Approved

    Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35]. … Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].

    Mixtures: Laser Block 100 sunblock, Ruby-Cell 4U Plus Sun
  6. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … endochondral ossification, resulting in multisystem complications including short stature.

  7. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.

  8. Drug

    Streptococcus pneumoniae type 1 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10319
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  9. Drug

    Streptococcus pneumoniae type 6b capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10324
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR
  10. Drug

    Streptococcus pneumoniae type 7f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10325
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: Prevnar 20, SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR